Shilpa Medicare Telangana facility receives 8 USFDA observations

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Read also: Shilpa Medicare gets CDSCO green light for Non-Alcoholic Fatty Liver Disease treatment

This facility is capable of manufacturing, packaging, testing, storage and distribution of sterile injectables, oral tablets and Capsules, and is supplying to US, Europe and other markets across the globe. The US sales of products manufactured at this plant was less than 1% of the total business of the company for the first half year of FY25-26 and less than 5% of the total business of the company for FY24-25. The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia.

Read also: Shilpa Medicare ink pact to sell 31 percent stake in Sravathi Advanced Process Technologies for Rs 49.6 crore

Shilpa Medicare is a global pharmaceutical company specializing in contract development and manufacturing services for small and large molecules. With a strong emphasis on oncology and a growing presence in biologics, the company offers comprehensive solutions from discovery to commercial supply. Shilpa Medicare operates R&D and manufacturing facilities, serving partners across North America, Europe, and Asia.

Read also: Shilpa Medicare gets initial authorization from EMA for Rivaroxaban Orodispersible Films